Article Figures & Data
Figures
- Figure 1
- Clinical outcomes corresponding to: A) NLR or B) PLT levels in patients with advanced gastric cancer following chemotherapy. NLR: neutrophil-to-lymphocyte ratio, PLR: platelet count, PR: partial response, SD: stable disease, PD: progressive disease
- Figure 2
- Kaplan-Meier curves for overall survival in patients with advanced gastric cancer following chemotherapy stratified by: A) post-treatment NLR; B) postchemotherapy-NLR/postchemotherapy-PLT; C) Borrmann type; and D) pathological type. NLR: neutrophil to lymphocyte ratio, HR: hazard ratio, CI: confidence interval, PLT: platelet count
Tables
- Table 1
- Relationship between clinicopathological features and neutrophil to lymphocyte ratio levels in patients with advanced gastric cancer following chemotherapy.
Clinical characteristics Total (n=259) Pre-treatment Post-treatment Dynamic change NLR>2.5 NLR≤2.5 P-values NLR>2.5 NLR≤2.5 P-values Increase Decrease P-values Age (years) ≤60 130 (50.2) 72 (55.4) 58 (44.6) 1.000 51 (39.2) 79 (60.8) 1.0 40 (30.8) 90 (69.2) 0.275 >60 129 (49.8) 71 (55.0) 58 (45.0) 50 (38.8) 79 (61.2) 49 (38.0) 80 (62.0) Gender Male 196 (75.2) 101 (51.5) 95 (48.5) 0.050 77 (39.3) 119 (60.7) 0.984 70 (35.7) 126 (64.3) 1.0 Female 63 (24.8) 42 (66.7) 21 (33.3) 24 (38.1) 39 (61.9) 19 (30.2) 44 (69.8) Regimen Paclitaxel-based 166 (64.1) 88 (53.0) 78 (47.0) 0.794 57 (34.3) 109 (65.7) 0.086 59 (35.5) 107 (64.5) 0.849 Fluorouracil-based 46 (17.8) 28 (60.9) 18 (39.1) 21 (45.7) 25 (54.3) 16 (34.8) 30 (65.2) Fluorouracil+paclitaxel 42 (16.2) 24 (57.1) 18 (42.9) 19 (45.2) 23 (54.8) 12 (28.6) 30 (71.4) Other 5 (1.9) 3 (60.0) 2 (40.0) 4 (80.0) 1 (20.0) 2 (40.0) 3 (60.0) Tumor site Gastric antrum 35 (13.5) 24 (68.6) 11 (31.4) 0.280 12 (34.3) 23 (65.7) 0.915 12 (34.3) 23 (65.7) 0.896 Stomach cardia 100 (38.6) 55 (55.0) 45 (45.0) 41 (41.0) 59 (59.0) 33 (33.0) 67 (67.0) Crossing site 50 (19.3) 28 (56.0) 22 (44.0) 19 (38.0) 31 (62.0) 16 (32.0) 34 (68.0) Gastric body 74 (28.6) 36 (48.6) 38 (51.4) 29 (39.2) 45 (60.8) 28 (37.8) 46 (62.2) Pathological type Tubular adenocarcinoma 101 (39.0) 52 (51.5) 49 (48.5) 0.624 36 (35.6) 65 (64.6) 0.191 31 (30.7) 70 (69.3) 0.585 Signet ring cell carcinoma 55 (21.2) 35 (63.6) 20 (36.4) 29 (52.7) 26 (47.3) 24 (43.6) 31 (56.4) Mucinous adenocarcinoma 27 (10.4) 15 (55.6) 12 (44.4) 11 (40.7) 16 (59.3) 9 (33.3) 18 (66.7) Papillary carcinoma 59 (22.8) 33 (55.9) 26 (44.1) 19 (32.2) 40 (67.8) 19 (32.2) 40 (67.8) Other 17 (6.6) 8 (47.1) 9 (52.9) 6 (35.3) 11 (64.7) 6 (35.3) 11 (64.7) Metastasis Organ* 112 (43.2) 64 (57.1) 48 (42.9) 0.000** 43 (38.4) 69 (61.6) 0.375 38 (33.9) 74 (66.1) 0.466 Distant lymph node† 32 (12.4) 12 (37.5) 20 (62.5) 10 (31.3) 22 (68.8) 13 (40.6) 19 (59.4) Peritoneal 59 (22.8) 23 (39.0) 36 (61.0) 21 (35.6) 38 (64.4) 23 (39.0) 36 (61.0) Multi-site‡ 56 (21.6) 44 (78.6) 12 (21.4) 27 (48.2) 29 (51.8) 15 (26.8) 41 (73.2) Borrmann type I 43 (16.6) 21 (48.8) 22 (51.2) 0.024** 11 (25.6) 32 (74.4) 0.007** 14 (32.6) 29 (67.4) 0.968 II 76 (29.3) 34 (44.7) 42 (55.3) 24 (31.6) 52 (68.4) 25 (32.9) 51 (67.1) III 103 (39.8) 61 (59.2) 42 (40.8) 44 (42.7) 59 (57.3) 37 (35.9) 66 (64.1) IV 37 (14.3) 27 (73.0) 10 (27.0) 22 (59.5) 15 (40.5) 13 (35.1) 24 (64.9) Values are presented as numbers and precentages (%).
NLR: neutrophil-to-lymphocyte ratio
↵* Include liver, lung, ovary, pancreas, colon, and bone.
↵† Next to the aorta, superior mesenteric, retroperitoneal and supraclavicular lymph nodes.
↵‡ Include distant organ and lymph node metastasis simultaneously; distant organ and peritoneal metastasis simultaneously; distant lymph node and peritoneal metastasis simultaneously; distant organ, distant lymph node and peritoneal metastasis simultaneous.
↵** A p-value of <0.05 is statistically significant using Chi-square test.
- Table 2
- Relationship between clinicopathological features and platelet count levels in patients with advanced gastric cancer following chemotherapy.
Clinical characteristics Total (n=259) Pre-treatment PLT Post-treatment PLT Dynamic change >300×109/L ≤300×109/L P-values >300×109/L ≤300×109/L P-values Increase Decrease P-values Age (years) >60 130 (50.2) 101 (77.7) 29 (22.3) 1.000 111 (85.4) 19 (14.6) 0.598 92 (70.8) 38 (29.2) 0.270 ≤60 129 (49.8) 100 (77.5) 29 (22.5) 114 (88.4) 15 (11.6) 82 (63.6) 47 (36.4) Gender Male 196 (75.2) 151 (77.0) 45 (23.0) 0.542 168 (85.7) 28 (14.3) 0.123 130 (66.3) 66 (33.7) 1.000 Female 63 (24.8) 50 (79.4) 13 (20.6) 57 (90.5) 6 (9.5) 44 (69.8) 19 (30.2) Regimen Paclitaxel-based 166 (64.1) 126 (75.9) 40 (24.1) 0.193 146 (88.0) 20 (12.0) 0.529 120 (72.3) 46 (27.7) 0.109 Fluorouracil-based 46 (17.8) 41 (89.1) 5 (10.9) 40 (87.0) 6 (13.0) 25 (54.3) 21 (45.7) Fluorouracil and paclitaxel 42 (16.2) 30 (71.4) 12 (28.6) 34 (81.0) 8 (19.0) 26 (61.9) 16 (38.1) Other 5 (1.9) 4 (80.0) 1 (20.0) 5 (100.0) 0 (0.0) 3 (60.0) 2 (40.0) Tumor site Gastric antrum 35 (13.5) 25 (71.4) 10 (28.6) 0.808 28 (80.0) 7 (20.0) 0.455 25 (71.4) 10 (28.6) 0.751 Stomach cardia 100 (38.6) 78 (78.0) 22 (22.0) 87 (87.0) 13 (13.0) 65 (65.0) 35 (35.0) Crossing 50 (19.3) 39 (78.0) 11 (22.0) 46 (92.0) 4 (8.0) 36 (72.0) 14 (28.0) Gastric body 74 (28.6) 59 (79.7) 15 (20.3) 64 (86.5) 10 (13.5) 48 (64.9) 26 (35.1) Pathological type Tubular adenocarcinoma 101 (39.0) 75 (74.3) 26 (25.7) 0.661 87 (86.1) 14 (13.9) 0.339 68 (67.3) 33 (32.7) 0.713 Signet ring cell carcinoma 55 (21.2) 41 (74.5) 14 (25.5) 44 (80.0) 11 (20.0) 35 (63.6) 20 (36.4) Mucinous adenocarcinoma 27 (10.4) 22 (81.5) 5 (18.5) 24 (88.9) 3 (11.1) 18 (66.7) 9 (33.3) Papillary carcinoma 59 (22.8) 49 (83.1) 10 (16.9) 55 (93.2) 4 (6.8) 39 (66.1) 20 (33.9) Other 17 (6.6) 14 (82.4) 3 (17.6) 15 (88.2) 2 (11.8) 14 (82.4) 3 (17.6) Metastasis Organ* 112 (43.2) 88 (78.6) 24 (21.4) 0.809 97 (86.6) 15 (13.4) 0.622 77 (68.8) 35 (31.3) 0.183 Distant lymph node† 32 (12.4) 23 (71.9) 9 (28.1) 30 (93.8) 2 (6.2) 24 (75.0) 8 (25.0) Peritoneal 59 (22.8) 45 (76.3) 14 (23.7) 51 (86.4) 8 (13.6) 33 (55.9) 26 (44.1) Multi-site‡ 56 (21.6) 45 (80.4) 11 (19.6) 47 (83.9) 9 (16.1) 40 (71.4) 16 (28.6) Borrmann type I 43 (16.6) 27 (62.8) 16 (37.2) 0.035** 41 (95.3) 2 (4.7) 0.065 30 (69.8) 13 (30.2) 0.164 II 76 (29.3) 57 (75.0) 19 (25.0) 67 (88.2) 9 (11.8) 56 (73.7) 20 (26.3) III 103 (39.8) 86 (83.5) 17 (16.5) 83 (80.6) 20 (19.4) 61 (59.2) 42 (40.8) IV 37 (14.3) 31 (83.8) 6 (16.2) 34 (91.9) 3 (8.1) 27 (73.0) 10 (27.0) Values are presented as numbers and precentages (%).
PLT: platelet count
↵* Include liver, lung, ovary, pancreas, colon, and bone.
↵† Next to the aorta, superior mesenteric, retroperitoneal and supraclavicular lymph nodes.
↵‡ Include distant organ and lymph node metastasis simultaneously; distant organ and peritoneal metastasis simultaneously; distant lymph node and peritoneal metastasis simultaneously; distant organ, distant lymph node and peritoneal metastasis simultaneous.
↵** A p-value of <0.05 is statistically significant using Chi-square test.
- Table 3
- Relationship between clinical outcomes and neutrophil-to-lymphocyte ratio levels in patients with advanced gastric cancer following chemotherapy.
Variables PR+SD (n=207) PD (n=52) P-values PR (n=59) PD+SD (n=200) P-values mOS (month) P-values NLR levels Pre-chemotherapy NLR >2.5 114 (55.1) 29 (55.8) 1.000 102 (51.0) 41 (69.5) 0.018* 12.0 0.220 Pre-chemotherapy NLR ≤2.5 93 (44.9) 23 (44.2) 98 (49.0) 18 (30.5) 15.0 Post-chemotherapy NLR >2.5 70 (33.8) 31 (59.6) 0.001* 85 (42.5) 16 (27.1) 0.048* 11.0 0.0557 Post-chemotherapy NLR ≤2.5 137 (66.2) 21 (40.4) 115 (57.5) 43 (72.9) 15.0 NLR increase 63 (30.4) 26 50.0) 0.013* 76 (38.0) 13 (22.0) 0.034* 13.0 0.531 NLR decrease 144 (69.6) 26 50.0) 124 (62.0) 46 (78.0) 15.0 PLT levels Pre-chemotherapy PLT >300×109/L 45 (21.7) 13 (25.0) 0.75 43 (21.5) 15 (25.4) 0.647 12.0 0.665 Pre-chemotherapy PLT ≤300×109/L 162 (78.3) 39 (75.0) 157 (78.5) 44 (74.6) 15.0 Post-chemotherapy PLT >300×109/L 22 (10.6) 12 (23.1) 0.032* 29 (14.5) 5 (8.5) 0.324 11.0 0.867 Post-chemotherapy PLT ≤300×109/L 185 (89.4) 40 (76.9) 171 (85.5) 54 (91.5) 15.0 PLT increase 67 (32.4) 18 (34.6) 0.886 69 (34.5) 16 (27.1) 0.366 13.0 0.875 PLT decrease 140 (67.6) 34 (65.4) 131 (65.5) 43 (72.9) 15.0 Values are presented as numbers and precentages (%).
NLR: neutrophil-to-lymphocyte ratio, PLR: platelet count, PR: partial response, SD: stable disease, PD: progressive disease
↵* A p-value of <0.05 is statistically significant using Chi-square test or independent t-test.
- Table 4
- Univariate and multivariate analyses of overall survival in patients with advanced gastric cancer following chemotherapy.
Variables Univariate analysis Multivariate analysis HR (95% CI) P-values HR (95% CI) P-values Papillary carcinoma 0.36 (0.26-0.49) <0.0001 0.51 (0.36-0.71) <0.0001 Signet ring cell carcinoma 4.77 (3.48-6.54) <0.0001 3.83 (2.71-5.42) <0.0001 Mucinous adenocarcinoma 2.20 (1.46-3.31) <0.0001 2.34 (1.52-3.60) <0.0001 Borramann IV type 1.92 (1.34-2.74) <0.0001 1.26 (0.86-1.85) 0.232 Post-chemotherapy NLR >2.5 1.36 (1.06-1.76) 0.020 1.11 (0.84-1.46) 0.479 Post-chemotherapy NLR >2.5 + post-chemotherapy PLT >300×109/L 2.02 (1.24-3.27) 0.004 1.31 (0.77-2.22) 0.315 Values are presented as hazard ratio (HR) and 95% confidence interval (CI). NLR: neutrophil-to-lymphocyte ratio, PLR: platelet count
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.